KRON vs. EQ, ALRN, CARM, EGRX, MURA, KZR, MNOV, CKPT, AEON, and VHAQ
Should you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Equillium (EQ), Aileron Therapeutics (ALRN), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), Mural Oncology (MURA), Kezar Life Sciences (KZR), MediciNova (MNOV), Checkpoint Therapeutics (CKPT), AEON Biopharma (AEON), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
Equillium has higher revenue and earnings than Kronos Bio. Equillium is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Equillium has a net margin of -32.01% compared to Equillium's net margin of -1,534.11%. Kronos Bio's return on equity of -51.20% beat Equillium's return on equity.
27.0% of Equillium shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 23.4% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Equillium received 15 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 82.50% of users gave Equillium an outperform vote while only 66.67% of users gave Kronos Bio an outperform vote.
In the previous week, Kronos Bio had 1 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Kronos Bio and 4 mentions for Equillium. Kronos Bio's average media sentiment score of 0.76 beat Equillium's score of 0.04 indicating that Equillium is being referred to more favorably in the media.
Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500.
Equillium presently has a consensus price target of $3.90, suggesting a potential upside of 153.25%. Kronos Bio has a consensus price target of $4.13, suggesting a potential upside of 320.15%. Given Equillium's higher possible upside, analysts clearly believe Kronos Bio is more favorable than Equillium.
Summary
Equillium beats Kronos Bio on 10 of the 16 factors compared between the two stocks.
Get Kronos Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kronos Bio Competitors List
Related Companies and Tools
